c-MET Overexpression Drives AKT Activation, and Combined Inhibition Synergistically Enhances Therapeutic Sensitivity in Non-Small-Cell Lung Cancer
Cells · 25.06.2026 · 15 (13) · 1155
DOI: 10.3390/cells15131155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 25.06.2026. Verfasst von Pratheesh Kumar Poyil und 4 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Therapeutics, Research & Innovation, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins c-met, Proto-Oncogene Proteins c-akt, Lung Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aberrant activation of c-MET signaling contributes to tumor progression and resistance to therapy in non-small-cell lung cancer (NSCLC), yet its therapeutic significance remains incompletely understood. In this study, we evaluated c-MET expression and its association with AKT activation and clinical outcomes using a tissue microarray cohort and publicly available datasets. c-MET overexpression was significantly associated with increased p-AKT expression and showed a trend toward poorer overall survival in the tissue microarray cohort, while analysis of the TCGA LUAD dataset confirmed a significant association with reduced survival (log-rank p = 0.0223; HR = 1.234, 95% CI: 1.029–1.480). Functional studies demonstrated that pharmacological inhibition of c-MET suppressed cell proliferation and induced caspase-dependent mitochondrial apoptosis in NSCLC cell lines. Mechanistically, c-MET inhibition resulted in AKT inactivation, identifying AKT as a key downstream mediator of c-MET signaling. Notably, combined inhibition of c-MET (PHA665752) and AKT (MK2206) exhibited strong synergistic effects, significantly enhancing apoptosis and reducing cell viability compared to single-agent treatments. These findings were further validated in vivo, where combination therapy markedly delayed tumor growth without significant toxicity. Collectively, our results highlight c-MET-driven AKT activation as a key oncogenic mechanism and support dual c-MET/AKT targeting as a promising therapeutic strategy for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Therapeutics, Research & Innovation, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
- Genomic Analytics, Research & Innovation, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
- Translational Oncology Research, Research & Innovation, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
ORCID-Profile: Pratheesh Kumar Poyil
Zitieren
APA
Poyil, P. K., Begum, R., Thangavel, S., Al-Obaisi, K., & Siraj, A. K. (2026). c-MET Overexpression Drives AKT Activation, and Combined Inhibition Synergistically Enhances Therapeutic Sensitivity in Non-Small-Cell Lung Cancer. Cells, 15(13), 1155. https://doi.org/10.3390/cells15131155
Vancouver
Poyil PK, Begum R, Thangavel S, Al-Obaisi K, Siraj AK. c-MET Overexpression Drives AKT Activation, and Combined Inhibition Synergistically Enhances Therapeutic Sensitivity in Non-Small-Cell Lung Cancer. Cells. 2026;15(13):1155. doi:10.3390/cells15131155
BibTeX
@article{Poyil2026,
author = {Poyil, Pratheesh Kumar and Begum, Rafia and Thangavel, Saravanan and Al-Obaisi, Khadija and Siraj, Abdul K},
title = {c-MET Overexpression Drives AKT Activation, and Combined Inhibition Synergistically Enhances Therapeutic Sensitivity in Non-Small-Cell Lung Cancer},
journal = {Cells},
year = {2026},
volume = {15},
number = {13},
pages = {1155},
doi = {10.3390/cells15131155}
}
EUVIMED